Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT05094336
Registration number
NCT05094336
Ethics application status
Date submitted
14/10/2021
Date registered
26/10/2021
Date last updated
9/05/2024
Titles & IDs
Public title
AMG 193, Methylthioadenosine (MTA) Cooperative Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor, Alone and in Combination With Docetaxel in Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid Tumors
Query!
Scientific title
A Phase 1/1b/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 193 Alone and in Combination With Docetaxel in Subjects With Advanced MTAP-null Solid Tumors
Query!
Secondary ID [1]
0
0
20210023
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
MTAP
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Advanced MTAP-null Solid Tumors
0
0
Query!
Condition category
Condition code
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - AMG 193
Treatment: Drugs - Docetaxel
Treatment: Drugs - Comparator AMG 193 Test Tablet
Experimental: Part 1a, Phase 1: AMG 193 Monotherapy Dose Exploration - Participants with MTAP-null solid tumors will receive escalating doses of AMG 193 to estimate the MTD and/or the RP2D.
A group of these participants in the United States (US) will have the option to take part in a Drug Substance Particle Size (DSPS) assessment. These participants will receive escalating doses of AMG 193 and a dose of a comparator AMG 193 test tablet.
Experimental: Part 1c, Phase 1: AMG 193 Monotherapy Dose Expansion - Participants will receive the identified MTD/RP2D of AMG 193 in the following cohort: MTAP-null or lost MTAP expression NSCLC.
Experimental: Part 2a, Phase 1: AMG 193 Dose Exploration + Docetaxel - Participants with MTAP-null NSCLC will receive escalating doses of AMG 193 + a fixed dose of docetaxel to estimate the MTD/RP2D of the combination.
Experimental: Part 2b, Phase 1: AMG 193 + Docetaxel Dose Expansion - Participants with MTAP-null NSCLC will receive the identified MTD/RP2D of AMG 193 + docetaxel.
Experimental: Part 3: AMG 193 Phase 2 - Participants with MTAP-null solid tumors will receive AMG 193.
Experimental: Part 1e, Phase 1: AMG 193 Monotherapy Dose Expansion - Participants will receive the identified selected dose/MTD of AMG 193 in the following cohort: MTAP-null BTC.
Experimental: Part 1f, Phase 1: AMG 193 Monotherapy Dose Expansion - Participants will receive the identified selected dose/MTD of AMG 193 in the following cohort:
MTAP-null head and neck squamous cell carcinoma (HNSCC)
Experimental: Part 1g, Phase 1: AMG 193 Monotherapy Dose Expansion - Participants will receive the identified selected dose/MTD of AMG 193 in the following cohort:
MTAP-null pancreatic adenocarcinoma
Experimental: Part 1h, Phase 1: AMG 193 Monotherapy Dose Expansion - Participants will receive the identified selected dose/MTD of AMG 193 in the following cohort: MTAP-null or lost MTAP expression solid tumors (other than lymphoma or primary brain tumor).
Experimental: Part 1i, Phase 1: AMG 193 Dose Optimization - Participants will receive a randomized dose optimization evaluation of AMG 193.
Experimental: Part 1j, Phase 1: AMG 193 DSPS Substudy (US Sites Only) - Participants will receive doses of AMG 193 and comparator AMG 193 test tables at different times in a fasted state.
Experimental: Part 1k, Phase 1: AMG 193 Food Effect Substudy (US Sites Only) - Participants will receive AMG 193 once on a fasted state and once after eating a standardized high-fat, high calorie meal.
Treatment: Drugs: AMG 193
AMG 193: Orally via tablet
Treatment: Drugs: Docetaxel
Docetaxel: Intravenous infusion
Treatment: Drugs: Comparator AMG 193 Test Tablet
Comparator AMG 193 test tablet: Orally via tablet. Only participants in the DSPS group of the Part 1a, Phase 1: AMG 193 Monotherapy Dose Exploration, and Part 1j, Phase 1 arms will receive comparator AMG 193 test tablet.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Parts 1 and 2: Number of Participants Who Experience a Dose-Limiting Toxicity (DLT)
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
28 days
Query!
Primary outcome [2]
0
0
Parts 1 and 2: Number of Participants Who Experience a Treatment-emergent Adverse Event (TEAE)
Query!
Assessment method [2]
0
0
Adverse events (AEs) are defined as any untoward medical occurrence in clinical study participant irrespective of a causal relationship with the study treatment. TEAEs are any event that occurs after the participant has received study treatment. Any clinically significant changes in vital signs, electrocardiograms (ECGs) and clinical laboratory tests will be recorded as TEAEs.
Serious AEs (SAEs) are defined as any event that meets at least 1 of the following serious criteria:
Results in death (fatal)
Requires in-patient hospitalization or prolongation of existing hospitalization
Results in persistent or significant disability/incapacity
Is a congenital anomaly/birth defect
Other medically important serious event
Query!
Timepoint [2]
0
0
Up to approximately 2 years
Query!
Primary outcome [3]
0
0
Part 3: Objective Response Rate (ORR)
Query!
Assessment method [3]
0
0
Query!
Timepoint [3]
0
0
Up to approximately 2 years
Query!
Secondary outcome [1]
0
0
Parts 1 and 2: Maximal Plasma Concentration (Cmax) of AMG 193
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
Cycle 1 Day 1 to Pre-Dose Cycle 5 Day 1 (Part 1 Cycle = 28 days, Part 2 Cycle =21 days)
Query!
Secondary outcome [2]
0
0
Parts 1 and 2: Time to Achieve Maximal Plasma Concentration (Tmax) of AMG 193
Query!
Assessment method [2]
0
0
Query!
Timepoint [2]
0
0
Cycle 1 Day 1 to Pre-Dose Cycle 5 Day 1 (Part 1 Cycle = 28 days, Part 2 Cycle =21 days)
Query!
Secondary outcome [3]
0
0
Parts 1 and 2: Area Under the Plasma Concentration Versus Time Curve (AUC) of AMG 193
Query!
Assessment method [3]
0
0
Query!
Timepoint [3]
0
0
Cycle 1 Day 1 to Pre-Dose Cycle 5 Day 1 (Part 1 Cycle = 28 days, Part 2 Cycle =21 days)
Query!
Secondary outcome [4]
0
0
Part 2 Only: Maximal Plasma Concentration (Cmax) of Docetaxel
Query!
Assessment method [4]
0
0
Query!
Timepoint [4]
0
0
Cycle 1 Day 1 to Pre-Dose Cycle 5 Day 1 (Cycle =21 days)
Query!
Secondary outcome [5]
0
0
Part 2 Only: Time to Achieve Maximal Plasma Concentration (Tmax) of Docetaxel
Query!
Assessment method [5]
0
0
Query!
Timepoint [5]
0
0
Cycle 1 Day 1 to Pre-Dose Cycle 5 Day 1 (Cycle =21 days)
Query!
Secondary outcome [6]
0
0
Part 2 Only: Area Under the Plasma Concentration Versus Time Curve (AUC) of Docetaxel
Query!
Assessment method [6]
0
0
Query!
Timepoint [6]
0
0
Cycle 1 Day 1 to Pre-Dose Cycle 5 Day 1 (Cycle =21 days)
Query!
Secondary outcome [7]
0
0
Parts 1 and 2: ORR
Query!
Assessment method [7]
0
0
Query!
Timepoint [7]
0
0
Up to approximately 2 years
Query!
Secondary outcome [8]
0
0
Parts 1, 2 and 3: Disease Control Rate (DCR)
Query!
Assessment method [8]
0
0
Query!
Timepoint [8]
0
0
Up to approximately 2 years
Query!
Secondary outcome [9]
0
0
Parts 1, 2 and 3: Duration of Response (DoR)
Query!
Assessment method [9]
0
0
Query!
Timepoint [9]
0
0
Up to approximately 2 years
Query!
Secondary outcome [10]
0
0
Parts 1, 2 and 3: Time to Response (TTR)
Query!
Assessment method [10]
0
0
Query!
Timepoint [10]
0
0
Up to approximately 2 years
Query!
Secondary outcome [11]
0
0
Parts 1, 2 and 3: Duration of Stable Disease (SD)
Query!
Assessment method [11]
0
0
Query!
Timepoint [11]
0
0
Up to approximately 2 years
Query!
Secondary outcome [12]
0
0
Parts 1, 2 and 3: Progression-Free Survival (PFS)
Query!
Assessment method [12]
0
0
Query!
Timepoint [12]
0
0
Up to approximately 2 years
Query!
Secondary outcome [13]
0
0
Parts 1, 2 and 3: Overall Survival (OS)
Query!
Assessment method [13]
0
0
Query!
Timepoint [13]
0
0
Up to approximately 2 years
Query!
Secondary outcome [14]
0
0
Part 3 Only: Number of Participants Who Experience TEAE
Query!
Assessment method [14]
0
0
AEs are defined as any untoward medical occurrence in clinical study participant irrespective of a causal relationship with the study treatment. TEAEs are any event that occurs after the participant has received study treatment. Any clinically significant changes in vital signs, ECGs and clinical laboratory tests will be recorded as TEAEs.
SAEs are defined as any event that meets at least 1 of the following serious criteria:
Results in death (fatal)
Requires in-patient hospitalization or prolongation of existing hospitalization
Results in persistent or significant disability/incapacity
Is a congenital anomaly/birth defect
Other medically important serious event
Query!
Timepoint [14]
0
0
Up to approximately 2 years
Query!
Secondary outcome [15]
0
0
Part 1a Only: Maximal Plasma Concentration (Cmax) of AMG 193
Query!
Assessment method [15]
0
0
Query!
Timepoint [15]
0
0
Cycle 2 Day 1 to pre-dose on Cycle 2 Day 2 (Cycle = 28 days)
Query!
Secondary outcome [16]
0
0
Part 1a Only: Time to Achieve Maximal Plasma Concentration (Tmax) of AMG 193
Query!
Assessment method [16]
0
0
Query!
Timepoint [16]
0
0
Cycle 2 Day 1 to pre-dose on Cycle 2 Day 2 (Cycle = 28 days)
Query!
Secondary outcome [17]
0
0
Part 1a Only: Area Under the Plasma Concentration Versus Time Curve (AUC) of AMG 193
Query!
Assessment method [17]
0
0
Query!
Timepoint [17]
0
0
Cycle 2 Day 1 to pre-dose on Cycle 2 Day 2 (Cycle = 28 days)
Query!
Secondary outcome [18]
0
0
Part 1a Only: Maximal Plasma Concentration (Cmax) of Comparator AMG 193 Test Tablet
Query!
Assessment method [18]
0
0
Query!
Timepoint [18]
0
0
Cycle 2 Day 2 to pre-dose on Cycle 2 Day 3 (Cycle = 28 days)
Query!
Secondary outcome [19]
0
0
Part 1a Only: Time to Achieve Maximal Plasma Concentration (Tmax) of Comparator AMG 193 Test Tablet
Query!
Assessment method [19]
0
0
Query!
Timepoint [19]
0
0
Cycle 2 Day 2 to pre-dose on Cycle 2 Day 3 (Cycle = 28 days)
Query!
Secondary outcome [20]
0
0
Part 1a Only: Area Under the Plasma Concentration Versus Time Curve (AUC) of Comparator AMG 193 Test Tablet
Query!
Assessment method [20]
0
0
Query!
Timepoint [20]
0
0
Cycle 2 Day 2 to pre-dose on Cycle 2 Day 3 (Cycle = 28 days)
Query!
Secondary outcome [21]
0
0
Part 1k Only: Cmax of AMG 193 during fasted state
Query!
Assessment method [21]
0
0
Query!
Timepoint [21]
0
0
Cycle 2 day 1 pre-dose up to 24 hours post-dose (Cycle = 28 days)
Query!
Secondary outcome [22]
0
0
Part 1k Only: Tmax of AMG 193 during fasted state
Query!
Assessment method [22]
0
0
Query!
Timepoint [22]
0
0
Cycle 2 day 1 pre-dose up to 24 hours post-dose (Cycle = 28 days)
Query!
Secondary outcome [23]
0
0
Part 1k Only: AUC of AMG 193 during fasted state
Query!
Assessment method [23]
0
0
Query!
Timepoint [23]
0
0
Cycle 2 day 1 pre-dose up to 24 hours post-dose (Cycle = 28 days)
Query!
Secondary outcome [24]
0
0
Part 1k Only: Cmax of AMG 193 during fed state
Query!
Assessment method [24]
0
0
Query!
Timepoint [24]
0
0
Cycle 2 day 2 pre-dose up to 24 hours post-dose (Cycle = 28 days)
Query!
Secondary outcome [25]
0
0
Part 1k Only: Tmax of AMG 193 during fed state
Query!
Assessment method [25]
0
0
Query!
Timepoint [25]
0
0
Cycle 2 day 2 pre-dose up to 24 hours post-dose (Cycle = 28 days)
Query!
Secondary outcome [26]
0
0
Part 1k Only: AUC of AMG 193 during fed state
Query!
Assessment method [26]
0
0
Query!
Timepoint [26]
0
0
Cycle 2 day 2 pre-dose up to 24 hours post-dose (Cycle = 28 days)
Query!
Eligibility
Key inclusion criteria
- Participant has provided informed consent/assent before initiation of any study
specific activities/procedures.
- Age = 18 years.
- Evidence of homozygous loss of cyclin dependent kinase inhibitor 2A (CDKN2A) (null)
(Parts 1a, 1j, 1k, and 2a only) and/or methylthioadenosine phosphorylase (MTAP) (null)
in the tumor tissue or blood (Parts 1a to 1k, Parts 2a and 2b) or lost MTAP expression
in the tumor tissue (Parts 1a to 1k, Parts 2a and 2b).
- Histologically confirmed metastatic or locally advanced solid tumor not amenable to
curative treatment with surgery and/or radiation.
- Able to swallow and retain orally (PO) administered study treatment and willing to
record daily adherence to investigational product.
- Disease measurable as defined by Response Evaluation Criteria in Solid Tumors Version
1.1 (RECIST v1.1).
Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.
- Adequate hematopoietic function per local laboratory
- Adequate renal function per local laboratory
- Adequate glucose control per local laboratory (Part 1 only)
- Adequate liver function per local laboratory
- Adequate coagulation parameters
- Adequate pulmonary function
- Adequate cardiac function
- Minimum life expectancy of 12 weeks as per investigator judgement.
- A total of 25 slides of archived tumor tissue (formalin-fixed, paraffin-embedded
[FFPE] sample collected within 5 years) or an archival block must be available.
- For Part 1f (MTAP-null or lost MTAP expression HNSCC): Must be willing to undergo
tumor biopsy.
- For Part 1a: Must be willing to undergo tumor biopsy, before start of treatment
(archival sample acceptable if obtained with 6 months of enrollment and subject has
not received any other treatment since sample was obtained) and while on treatment.
- Part 1i: Enrollment criteria for Part 1i are to match the criteria of the expansion
arm from which the indication was selected.
- For DSPS study (Part 1j): Must be willing to participate in DSPS substudy (US sites
only).
Food Effect Substudy (Part 1k): Specific Inclusion Criteria
- Subject able and willing to eat a standardized high-fat, high-caloric meal
- Subject able and willing to fast for = 6 hours
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
100
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Spinal cord compression or untreated brain metastases or leptomeningeal disease.
- History of other malignancy within the past 2 years
- Any evidence of current interstitial lung disease
- Active infection
- Evidence of active severe acute respiratory syndrome coronavirus 2 (SARS-COV2)
infection.
- History of arterial thrombosis
- Myocardial infarction and/or symptomatic congestive heart failure.
- Gastrointestinal tract disease
- History of bowel obstruction, abdominal fistula, gastrointestinal perforation, or
intra-abdominal abscess
- History of solid organ transplant.
- Diagnosis of Congenital Short QT Syndrome.
- Major surgery
- Anti-tumor therapy within 28 days of study day 1, unless anti-tumor therapy is a
therapy with 5 times the half-life being shorter than 28 days
- Prior treatment with an methionine adenosyltransferase 2a (MAT2A) inhibitor or a
protein arginine methyltransferase 5 (PRMT5) inhibitor.
- Prior treatment with docetaxel (Part 2 only)
- Prior irradiation to 25% of the bone marrow.
- Therapeutic or palliative radiation therapy within 2 weeks of study day 1.
- Live vaccine therapy within 4 weeks before study drug administration.
- Use of therapeutic anti-coagulation for treatment of active thromboembolic events.
- Use of prescription medications that are known strong inducers of cytochrome P450 3A4
(CYP3A4) within 14 days or 5 half-lives (whichever is longer) before study day 1
- Unresolved toxicity from prior anti-cancer therapy
- Currently receiving treatment in another investigational device or drug study
- Known positive test for Human Immunodeficiency Virus (HIV).
- Positive hepatitis B surface antigen
- positive hepatitis C virus ribonucleic acid (RNA) by polymerase chain reaction (PCR)
- Female participants of childbearing potential unwilling to use protocol specified
method of contraception
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Non-randomised trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Other
Query!
Other design features
Query!
Phase
Phase 1/Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/02/2022
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
12/03/2029
Query!
Actual
Query!
Sample size
Target
527
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
NSW
Query!
Recruitment hospital [1]
0
0
Chris OBrien Lifehouse - Camperdown
Query!
Recruitment postcode(s) [1]
0
0
2050 - Camperdown
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
California
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Indiana
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Maryland
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Missouri
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
New York
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
North Carolina
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Ohio
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Pennsylvania
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Texas
Query!
Country [10]
0
0
Austria
Query!
State/province [10]
0
0
Graz
Query!
Country [11]
0
0
Austria
Query!
State/province [11]
0
0
Salzburg
Query!
Country [12]
0
0
Belgium
Query!
State/province [12]
0
0
Bruxelles
Query!
Country [13]
0
0
Belgium
Query!
State/province [13]
0
0
Edegem
Query!
Country [14]
0
0
Belgium
Query!
State/province [14]
0
0
Gent
Query!
Country [15]
0
0
Belgium
Query!
State/province [15]
0
0
Hasselt
Query!
Country [16]
0
0
Belgium
Query!
State/province [16]
0
0
Leuven
Query!
Country [17]
0
0
Canada
Query!
State/province [17]
0
0
Alberta
Query!
Country [18]
0
0
Canada
Query!
State/province [18]
0
0
Ontario
Query!
Country [19]
0
0
France
Query!
State/province [19]
0
0
Dijon cedex
Query!
Country [20]
0
0
France
Query!
State/province [20]
0
0
Lille
Query!
Country [21]
0
0
France
Query!
State/province [21]
0
0
Villejuif
Query!
Country [22]
0
0
Germany
Query!
State/province [22]
0
0
Halle (Saale)
Query!
Country [23]
0
0
Germany
Query!
State/province [23]
0
0
Heidelberg
Query!
Country [24]
0
0
Germany
Query!
State/province [24]
0
0
Ulm
Query!
Country [25]
0
0
Germany
Query!
State/province [25]
0
0
Wuerzburg
Query!
Country [26]
0
0
Hong Kong
Query!
State/province [26]
0
0
Hong Kong
Query!
Country [27]
0
0
Hong Kong
Query!
State/province [27]
0
0
Shatin, New Territories
Query!
Country [28]
0
0
Japan
Query!
State/province [28]
0
0
Aichi
Query!
Country [29]
0
0
Japan
Query!
State/province [29]
0
0
Chiba
Query!
Country [30]
0
0
Japan
Query!
State/province [30]
0
0
Tokyo
Query!
Country [31]
0
0
Korea, Republic of
Query!
State/province [31]
0
0
Seongnam-si, Gyeonggi-do
Query!
Country [32]
0
0
Korea, Republic of
Query!
State/province [32]
0
0
Seoul
Query!
Country [33]
0
0
Switzerland
Query!
State/province [33]
0
0
Bellinzona
Query!
Country [34]
0
0
Switzerland
Query!
State/province [34]
0
0
Bern
Query!
Country [35]
0
0
Switzerland
Query!
State/province [35]
0
0
Geneve 14
Query!
Country [36]
0
0
Taiwan
Query!
State/province [36]
0
0
Tainan
Query!
Country [37]
0
0
Taiwan
Query!
State/province [37]
0
0
Taipei
Query!
Country [38]
0
0
Taiwan
Query!
State/province [38]
0
0
Taoyuan
Query!
Country [39]
0
0
United Kingdom
Query!
State/province [39]
0
0
London
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Amgen
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The primary objective of Parts 1 and 2 of this study is to evaluate the safety, tolerability,
and to determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) of AMG
193 alone and in combination with docetaxel in adult participants with metastatic or locally
advanced methylthioadenosine phosphorylase (MTAP)-null solid tumors.
The primary objective of Part 3 of this study is to evaluate the objective response rate
(ORR) of AMG 193 in adult participants with metastatic or locally advanced MTAP-null solid
tumors.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT05094336
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
MD
Query!
Address
0
0
Amgen
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Amgen Call Center
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
866-572-6436
Query!
Fax
0
0
Query!
Email
0
0
[email protected]
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT05094336
Download to PDF